IMC-P115C

IMC-P115C is a half-life extended (HLE) ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) bispecific protein developed by Immunocore. It targets the PReferentially expressed Antigen in MElanoma (PRAME) peptide presented by HLA-A*02:01 and engages CD3 on T cells, redirecting the immune system to recognize and kill cancer cells. The molecule is designed to improve patient convenience by reducing dosing frequency compared to earlier candidates. IMC-P115C uses the same CD3 effector and TCR specificity as brenetafusp, another Immunocore candidate, but with an extended half-life for less frequent administration. Its mechanism of action involves high-affinity binding to intracellular PRAME antigens via engineered soluble T cell receptors, coupled with anti-CD3 immune activation for targeted tumor cell killing. The drug is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors expressing PRAME who are HLA-A*02:01-positive[1][4][5][6][7].

Other names

PRAME-HLE-A02PRAME-HLE-A-02PRAME-HLE-A 02